In Brief: Rochester Medical
This article was originally published in The Gray Sheet
Executive Summary
Rochester Medical: Randomized, 400 patient clinical study conducted at the University of Wisconsin, Madison, shows the firm's nitrofurazone-impregnated antibacterial Foley catheter is associated with a lower incidence of catheter-related bacterial urinary tract infections than non-medicated catheters in patients catheterized from one to seven days. The company, which expects to submit a 510(k) for the device within the next several months, claims that patients with non-medicated catheters had three times the rate of bacterial infections. "No adverse reactions were seen" with the device, said lead investigator Dennis Make, MD, University of Wisconsin Medical School, Madison, Wisconsin...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.